NCT06546917 bWell-D Pilot Randomized Controlled Trial
| NCT ID | NCT06546917 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of British Columbia |
| Condition | Depressive Disorder, Major |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-01-01 |
| Primary Completion | 2026-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-01-01 with a primary completion date of 2026-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to determine the acceptability, feasibility, and validity of the bWell Cognitive Care Platform for Depression (bWell-D), a novel Virtual Reality (VR) cognitive assessment and remediation tool, in depressed populations. The main questions are: * Do patients with Major Depressive Disorder (MDD) find the bWell-D cognitive assessment battery and protocol feasible, tolerable, and acceptable? * Do patients with Major Depressive Disorder (MDD) find the 8 week bWell-D remediation protocol feasible, tolerable, and acceptable? Following initial cognitive assessment, researchers will assess feasibility outcomes in the bWell remediation arm to a VR scenes experience arm to learn more about the feasibility of bWell for cognitive assessment and remediation. Patients will: * Complete an initial bWell cognitive assessment session * Randomized to either receive bWell cognitive remediation or a VR scenes experience twice a week for eight weeks * Complete cognitive/functional/clinical assessments and EEG at baseline, midpoint and endpoint of the remediation protocol, as well as two MRI scans and measures of tolerability, engagement, and enjoyment
Eligibility Criteria
Inclusion Criteria: * 19-55 years old * Meeting the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for MDD as assessed by a standardized psychiatric interview (SCID-5-RV) conducted by a trained clinician. * Patients will be euthymic or mildly depressed (defined by a Montgomery-Asberg Depression Rating Scale \[MADRS\] score \< 19) * Patients will report subjective cognitive deficits at baseline, as indicated by a total Perceived Deficits Questionnaire - Depression 20 \[PDQ-D-20\] score \> 20 at study enrollment. * If using antidepressants, participants will be on stable antidepressant therapy for at least 4 weeks prior to randomization. All concomitant doctor-prescribed medications must be at a stable dose for 4 weeks prior to the randomization visit. * If undergoing psychotherapy, participants will be on stable adjunct psychotherapy for at least 8 weeks prior to randomization * If comorbid diagnosis of attention deficit hyperactivity disorder (ADHD), patients must be on stable dose of stimulants for at least 4 weeks prior to randomization. * Participants will be able to follow written and verbal instructions in English Exclusion Criteria: * Moderate - severely depressed patients will be excluded at this point due to acceptability concerns (e.g. potential for cybersickness) * Presence of significant neurological disorders, head trauma, or other unstable medical conditions. These conditions may adversely impact cognitive functioning and influence study results. * Presence of other psychiatric disorder (e.g. anxiety, psychotic disorder) that may be considered primary. * Meeting DSM-5 criteria for alcohol or other substance use disorder within three months prior to the randomization visit.\* * Use of benzodiazepine medications more than three times per week and/or within 24 hours of baseline or close out visit * Use of cannabis or alcohol within 24 hours, or tobacco within 30 minutes of baseline or close out visit * Suicidal ideation or self harm * Completion of previous cognitive remediation Additionally, patients will be excluded from the study if they meet any of the following criteria due to contraindications with MRI scanning: * Retained wires from an electronic implant that has been removed (i.e. pacemaker wires not attached to a pacemaker) * Cardiac pacemaker or defibrillator * Metal in eye or orbit * Ferromagnetic aneurysm clip * Pregnancy * Makeup tattoos that are not designed to fade over time * Stainless steel intrauterine device (IUD) Depending on the individual situation, they MAY NOT be able to participate if they have/had any of the following: * Artificial Heart Valve * Ear or eye implant * Brain aneurysm clip * Implanted electronic device (i.e. drug infusion pump, electrical stimulator) * Coil, catheter, or filter in any blood vessel * Orthopedic hardware (artificial joint, plate, screw, rod) * Shrapnel, bullets, or other metal fragments * Surgery, medical procedure or tattoos (including tattooed eyeliner) in the last six weeks * Other metallic prostheses If the participant has any of the above, or any safety issues arise during MRI screening process, the individual case will be reviewed by UBC Hospital MR Technologist and/or Radiologist and a case-by-case decision will be made regarding participation. Additionally, for the healthy participant recruitment, the eligibility criteria is as follows: Inclusion Criteria for healthy controls: \- 19-55 years old Exclusion criteria for healthy controls: * History of any psychiatric disorder, as assessed by a standardized psychiatric diagnostic interview * Presence of significant neurological disorder, head trauma, or other unstable medical conditions which may adversely impact cognitive functioning * Presence of any physical mobility issues that limit arm or neck movement
Contact & Investigator
Trisha Chakrabarty, MD
PRINCIPAL INVESTIGATOR
University of British Columbia
Frequently Asked Questions
Who can join the NCT06546917 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, up to 55 Years, studying Depressive Disorder, Major. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06546917 currently recruiting?
Yes, NCT06546917 is actively recruiting participants. Contact the research team at trisha.chakrabarty@ubc.ca for enrollment information.
Where is the NCT06546917 trial being conducted?
This trial is being conducted at Vancouver, Canada.
Who is sponsoring the NCT06546917 clinical trial?
NCT06546917 is sponsored by University of British Columbia. The principal investigator is Trisha Chakrabarty, MD at University of British Columbia. The trial plans to enroll 40 participants.